French orthopedic implants maker Implanet's nine-month revenue jumps, partly on strong US momentum

By Reuters News


Overview

  • France orthopedic implants maker's nine-month 2026 revenue grew 21% yr/yr to €10.6 mln

  • Q3 2026 revenue rose 18% yr/yr to €3.44 mln

  • Growth driven by expansion in Spine Implants and Medical Equipment, strong US momentum


Outlook

  • Company plans to reinforce U.S. commercial team and accelerate rollout of JAZZ and co-developed products

  • Implanet aims to expand JSS and Sanyou Medical product lines in France, U.S. and internationally

  • Company to launch SMTP Quntas range and expand distribution of Sanyou Medical surgical technologies


Result Drivers

  • JSS SYSTEM SALES - Co said doubling sales of new JSS hybrid posterior fixation system boosted Spine Implants revenue

  • MEDICAL EQUIPMENT - Continued rollout of SMTP ultrasonic scalpel drove Medical Equipment revenue higher

  • US GROWTH - Co said strong US sales contributed significantly to overall revenue increase


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

EUR 10.6 mln


Reuters Recommended Reads

  • Oct 12 - France's LVMH nine-month revenue slips amid weak Q3 demand in China


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk